PMID- 23615455
OWN - NLM
STAT- MEDLINE
DCOM- 20131017
LR  - 20190727
IS  - 1349-3329 (Electronic)
IS  - 0040-8727 (Linking)
VI  - 229
IP  - 4
DP  - 2013 Apr
TI  - Expression of CD133 in neuroendocrine neoplasms of the digestive tract: a 
      detailed immunohistochemical analysis.
PG  - 301-9
AB  - Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are potentially malignant 
      with variable biologic behavior that originates from neuroendocrine cells of 
      digestive tract. Recently, the existence of cancer stem cells (CSC) was 
      demonstrated in tumors of gastrointestinal tract. CD133 is a transmembrane 
      glycoprotein that serves as a CSC marker in various malignancies. However, the 
      expression of CD133 in neuroendocrine neoplasms (NEN) of digestive tract has not 
      been studied. We evaluated tissue expression of CD133 by immunohistochemistry in 
      90 NENs of digestive tract with their matched non-neoplastic mucosa including 
      stomach (n=15), small intestine (n=7), appendix (n=3), colon (n=8), rectum 
      (n=41), pancreas (n=2), gallbladder (n=4) and liver (n=10). Tumors were divided 
      according to 2010 WHO classification. CD133 was expressed in 30.3% (17/56) of 
      well-differentiated neuroendocrine tumors (NET), 26.1% (6/23) of 
      poorly-differentiated neuroendocrine carcinomas (NEC) and 63.6% (7/11) of mixed 
      adenoneuroendocrine carcinoma (MANECs). MANEC refers to existence of both 
      adenocarcinoma and NEC together, each one comprising at least 30% of the tumor. 
      CD133 was expressed in cytoplasm, luminal-side of cell membrane, or both and the 
      staining pattern correlated with tumor growth pattern. CD133 expression was not 
      significantly correlated with tumor grade, site, expression of neuroendocrine 
      markers (chromogranin-A and synaptophysin) and patients' survival. Thus, CD133 
      expression may lack prognostic significance in GEP-NETs. Importantly, CD133 was 
      not detectable in non-neoplastic neuroendocrine cells of digestive system 
      including pancreatic islets. In conclusion, CD133 is expressed in 
      poorly-differentiated NECs and well-differentiated NETs of the digestive tract.
FAU - Mia-Jan, Khalilullah
AU  - Mia-Jan K
AD  - Department of pathology, Yonsei University Wonju College of Medicine, Wonju, 
      Gangwon-do, Korea.
FAU - Munkhdelger, Jijgee
AU  - Munkhdelger J
FAU - Lee, Mi-Ra
AU  - Lee MR
FAU - Ji, Sun-Young
AU  - Ji SY
FAU - Kang, Tae Young
AU  - Kang TY
FAU - Choi, EunHee
AU  - Choi E
FAU - Cho, Mee-Yon
AU  - Cho MY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - 0 (AC133 Antigen)
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Glycoproteins)
RN  - 0 (PROM1 protein, human)
RN  - 0 (Peptides)
SB  - IM
MH  - AC133 Antigen
MH  - Antigens, CD/*metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Digestive System Neoplasms/*metabolism/pathology
MH  - Glycoproteins/*metabolism
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Neoplastic Stem Cells/*metabolism
MH  - Neuroendocrine Tumors/*metabolism/pathology
MH  - Peptides/*metabolism
MH  - Republic of Korea
EDAT- 2013/04/26 06:00
MHDA- 2013/10/18 06:00
CRDT- 2013/04/26 06:00
PHST- 2013/04/26 06:00 [entrez]
PHST- 2013/04/26 06:00 [pubmed]
PHST- 2013/10/18 06:00 [medline]
AID - DN/JST.JSTAGE/tjem/229.301 [pii]
AID - 10.1620/tjem.229.301 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2013 Apr;229(4):301-9. doi: 10.1620/tjem.229.301.